BR9907884A - Vaccine composition, processes for generating an immune response in a pneumococcal antigen, for increasing ifn-gamma response in a pneumococcal vaccine, and for generating complementary attachment antibodies for a protective response to a pathogen, immunogenic composition, and, process for generating an immune response in a meningococcal antigen - Google Patents

Vaccine composition, processes for generating an immune response in a pneumococcal antigen, for increasing ifn-gamma response in a pneumococcal vaccine, and for generating complementary attachment antibodies for a protective response to a pathogen, immunogenic composition, and, process for generating an immune response in a meningococcal antigen

Info

Publication number
BR9907884A
BR9907884A BR9907884-8A BR9907884A BR9907884A BR 9907884 A BR9907884 A BR 9907884A BR 9907884 A BR9907884 A BR 9907884A BR 9907884 A BR9907884 A BR 9907884A
Authority
BR
Brazil
Prior art keywords
generating
antigen
response
immune response
pneumococcal
Prior art date
Application number
BR9907884-8A
Other languages
Portuguese (pt)
Inventor
Vincent J Laposta
John H Eldridge
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of BR9907884A publication Critical patent/BR9907884A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçãO DE VACINA, PROCESSOS PARA GERAR UMA RESPOSTA IMUNE EM UM ANTìGENO PNEUMOCóCICO, PARA AUMENTAR RESPOSTA DE IFN-GAMA EM UMA VACINA PNEUMOCóCICA, E PARA GERAR ANTICORPOS DE FIXAçãO COMPLEMENTAR PARA UMA RESPOSTA PROTETORA A UM PATóGENO, COMPOSIçãO IMUNOGêNICA, E, PROCESSO PARA GERAR UMA RESPOSTA IMUNE EM UM ANTìGENO MENINGOCóCICO". Esta invenção refere-se às composições de vacina compreendendo uma mistrua de antígeno, tal como um antígeno pneumocócico ou meningocócico, e interleucina IL-12, que pode ser adsorvida sobre um mineral em suspensão. O antígeno pneumocócico ou meningocócico pode ser conjugado em uma molécula veículo. Estas composições de vacina modulam a resposta imune protetora ao antígeno."VACCINE COMPOSITION, PROCESSES TO GENERATE AN IMMUNE RESPONSE IN A PNEUMOCOCCY ANTIGEN, TO INCREASE IFN-RANGE RESPONSE IN A PNEUMOCOCCY VACCINE, AND TO GENERATE COMPLEMENTARY FIXING ANTIBODIES, A PROTECTIVE PROTECTION, A PROTECTIVE PROTECTION AND A PROTECTIVE PROTECTIVE PROTECTIVE PROTECTION. GENERATE AN IMMUNE RESPONSE IN A MENINGOCOCCIC ANTIGEN ". This invention relates to vaccine compositions comprising an antigen mix, such as a pneumococcal or meningococcal antigen, and IL-12 interleukin, which can be adsorbed onto a suspended mineral. The pneumococcal or meningococcal antigen can be conjugated to a carrier molecule. These vaccine compositions modulate the protective immune response to the antigen.

BR9907884-8A 1998-02-12 1999-02-10 Vaccine composition, processes for generating an immune response in a pneumococcal antigen, for increasing ifn-gamma response in a pneumococcal vaccine, and for generating complementary attachment antibodies for a protective response to a pathogen, immunogenic composition, and, process for generating an immune response in a meningococcal antigen BR9907884A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7452898P 1998-02-12 1998-02-12
PCT/US1999/002847 WO1999040936A2 (en) 1998-02-12 1999-02-10 Pneumococcal and meningococcal vaccines formulated with interleukin-12

Publications (1)

Publication Number Publication Date
BR9907884A true BR9907884A (en) 2000-10-24

Family

ID=22120049

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9907884-8A BR9907884A (en) 1998-02-12 1999-02-10 Vaccine composition, processes for generating an immune response in a pneumococcal antigen, for increasing ifn-gamma response in a pneumococcal vaccine, and for generating complementary attachment antibodies for a protective response to a pathogen, immunogenic composition, and, process for generating an immune response in a meningococcal antigen

Country Status (9)

Country Link
EP (1) EP1053015A2 (en)
JP (3) JP2002502882A (en)
KR (1) KR100585408B1 (en)
CN (1) CN1200730C (en)
AU (1) AU759391B2 (en)
BR (1) BR9907884A (en)
CA (1) CA2320223A1 (en)
IL (2) IL137809A0 (en)
WO (1) WO1999040936A2 (en)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9907884A (en) * 1998-02-12 2000-10-24 American Cyanamid Co Vaccine composition, processes for generating an immune response in a pneumococcal antigen, for increasing ifn-gamma response in a pneumococcal vaccine, and for generating complementary attachment antibodies for a protective response to a pathogen, immunogenic composition, and, process for generating an immune response in a meningococcal antigen
US6908757B1 (en) 1998-03-26 2005-06-21 The Procter & Gamble Company Serine protease variants having amino acid deletions and substitutions
US6946128B1 (en) 1999-07-22 2005-09-20 The Procter & Gamble Company Protease conjugates having sterically protected epitope regions
CZ2002212A3 (en) 1999-07-22 2002-07-17 The Procter & Gamble Company Variants of subtilisin protease having amino acid substitutions in defined epitope regions
CN1373802A (en) 1999-07-22 2002-10-09 宝洁公司 Subtilisin protease variants having amino acid deletions and substitutions in defined epitope regions
MXPA02000842A (en) 1999-07-22 2002-07-30 Procter & Gamble Protease conjugates having sterically protected clip sites.
SI1549338T1 (en) 2002-10-11 2011-04-29 Novartis Vaccines & Diagnostic Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
CA2514328C (en) 2003-01-30 2020-01-14 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
EP1961426B1 (en) 2003-10-02 2011-04-27 Novartis Vaccines and Diagnostics S.r.l. Combined meningitis vaccines
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
SI1740217T1 (en) 2004-04-30 2011-10-28 Novartis Ag Meningococcal conjugate vaccination
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
US8758764B2 (en) 2005-02-18 2014-06-24 Novartis Vaccines And Diagnostics Srl Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli
CN101203529A (en) 2005-02-18 2008-06-18 诺华疫苗和诊断公司 Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
CN113198012A (en) * 2005-04-08 2021-08-03 惠氏有限责任公司 Multivalent pneumococcal polysaccharide-protein conjugate composition
WO2006123164A2 (en) * 2005-05-19 2006-11-23 The Edward Jenner Institute For Vaccine Research Lps-binding and bactericidal cytokines and interferons
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
CA2659552A1 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
EP2886551A3 (en) 2008-02-21 2015-09-23 Novartis AG Meningococcal fhbp polypeptides
EP3549602A1 (en) 2009-03-06 2019-10-09 GlaxoSmithKline Biologicals S.A. Chlamydia antigens
US8679505B2 (en) 2009-04-14 2014-03-25 Novartis Ag Compositions for immunising against Staphylococcus aureus
SG177533A1 (en) 2009-07-07 2012-02-28 Novartis Ag Conserved escherichia coli immunogens
DK2464658T3 (en) 2009-07-16 2014-12-15 Novartis Ag Detoxified escherichia coli immunogens
NZ598458A (en) 2009-08-27 2014-03-28 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
US20120237536A1 (en) 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
US20130022639A1 (en) 2009-09-30 2013-01-24 Novartis Ag Expression of meningococcal fhbp polypeptides
BR112012009014B8 (en) 2009-09-30 2022-10-04 Novartis Ag PROCESS FOR PREPARING S. AUREUS CAPSULAR POLYSACCHARIDE CONJUGATE TYPE 5 OR TYPE 8 AND CRM197 TRANSPORT MOLECULE, CONJUGATE AND IMMUNOGENIC COMPOSITION
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
CN102917730A (en) 2009-10-27 2013-02-06 诺华有限公司 Modified meningococcal fHBP polypeptides
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
JP5781542B2 (en) 2009-12-30 2015-09-24 ノバルティス アーゲー E. polysaccharide immunogen conjugated to an E. coli carrier protein
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
JP2013529894A (en) 2010-04-07 2013-07-25 ノバルティス アーゲー Method for generating parvovirus B19 virus-like particles
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
WO2012006293A1 (en) 2010-07-06 2012-01-12 Novartis Ag Norovirus derived immunogenic compositions and methods
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
GB201017519D0 (en) 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
EP2655389A2 (en) 2010-12-24 2013-10-30 Novartis AG Compounds
US10030052B2 (en) 2011-07-25 2018-07-24 Glaxosmithkline Biologicals Sa Parvovirus Vp1 unique region polypeptides and compositions thereof
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
US9511130B2 (en) 2011-09-14 2016-12-06 Glaxosmithkline Biologicals Sa Escherichia coli vaccine combination
EP2755683B1 (en) 2011-09-14 2019-04-03 GlaxoSmithKline Biologicals SA Methods for making saccharide-protein glycoconjugates
US9694063B2 (en) 2011-12-08 2017-07-04 Glaxosmithkline Biologicals Sa Clostridium difficile toxin-based vaccine
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
MX2014010011A (en) 2012-02-24 2014-09-08 Novartis Ag Pilus proteins and compositions.
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
WO2013160335A2 (en) 2012-04-26 2013-10-31 Novartis Ag Antigens and antigen combinations
MX2014014067A (en) 2012-05-22 2015-02-04 Novartis Ag Meningococcus serogroup x conjugate.
CN104602702B (en) 2012-09-18 2021-08-27 葛兰素史密丝克莱恩生物有限公司 Outer membrane vesicles
ES2672996T3 (en) 2012-10-02 2018-06-19 Glaxosmithkline Biologicals Sa Non-linear saccharide conjugates
SG10201702685WA (en) 2012-10-03 2017-04-27 Glaxosmithkline Biolog Sa Immunogenic composition
CA2892688A1 (en) 2012-11-30 2014-06-05 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN114544913B (en) * 2022-02-23 2024-04-09 沈阳建筑大学 Soil investigation encryption sampling distribution optimization method

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
EP0769019A1 (en) * 1994-07-01 1997-04-23 Rican Limited Helicobacter pylori antigenic protein preparation and immunoassays
MX9702396A (en) * 1994-10-05 1997-12-31 Univ Vanderbilt Interleukin-12 as an adjuvant for paramyxoviridae vaccines.
GB9422990D0 (en) * 1994-11-15 1995-01-04 Cortecs Ltd Immunogenic compositions
US5866134A (en) * 1995-03-24 1999-02-02 Schering Corporation Method for enhancing the antibody response to specific antigens with Interleukin-10
WO1998008947A1 (en) * 1995-12-19 1998-03-05 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Enhancement of dna immunization through the use of cytokines
ES2262181T3 (en) * 1996-05-31 2006-11-16 National University Of Ireland, Maynooth IL-12 AS AN ASSISTANT IN THE VACCINE AGAINST THE BORDETELLA PERTUSSIS SPECIES.
US6438586B1 (en) * 1996-09-30 2002-08-20 Emc Corporation File transfer utility which employs an intermediate data storage system
BR9907884A (en) * 1998-02-12 2000-10-24 American Cyanamid Co Vaccine composition, processes for generating an immune response in a pneumococcal antigen, for increasing ifn-gamma response in a pneumococcal vaccine, and for generating complementary attachment antibodies for a protective response to a pathogen, immunogenic composition, and, process for generating an immune response in a meningococcal antigen
US6303114B1 (en) * 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens

Also Published As

Publication number Publication date
JP2010006827A (en) 2010-01-14
EP1053015A2 (en) 2000-11-22
AU2596599A (en) 1999-08-30
CN1292706A (en) 2001-04-25
KR100585408B1 (en) 2006-06-01
IL137809A (en) 2007-12-03
JP2010265279A (en) 2010-11-25
CA2320223A1 (en) 1999-08-19
AU759391B2 (en) 2003-04-10
CN1200730C (en) 2005-05-11
JP2002502882A (en) 2002-01-29
IL137809A0 (en) 2001-10-31
WO1999040936A2 (en) 1999-08-19
KR20010040898A (en) 2001-05-15
WO1999040936A3 (en) 1999-10-28

Similar Documents

Publication Publication Date Title
BR9907884A (en) Vaccine composition, processes for generating an immune response in a pneumococcal antigen, for increasing ifn-gamma response in a pneumococcal vaccine, and for generating complementary attachment antibodies for a protective response to a pathogen, immunogenic composition, and, process for generating an immune response in a meningococcal antigen
PT1187629E (en) ADJUVANT COMPOSITION THAT UNDERSTANDS SAPONIN AND AN IMMUNOSTIMULATOR OLIGONUCLEOTIDE
DE60141773D1 (en) GREAT SIMILAR RECEPTOR 5-LIGANDS AND USE PROCESS
ES2179261T3 (en) STREPTOCOCCUS EQUI BASED VACCINE.
MX9702336A (en) Vaccine compositions.
ZA917356B (en) Vaccine compositions
HUT69938A (en) Urease-based vaccine against helicobacter infection
AU4622693A (en) Potentiation of immunogenic response
DE60045668D1 (en) Influenza virus vaccine composition
BRPI0012196B8 (en) industrialized article
IS4518A (en) New vaccine formulation
BRPI0314373B8 (en) stable immunogenic product for the induction of antibodies against one or more antigenic proteins in an individual, pharmaceutical, immunogenic and vaccine compositions and process for preparing an immunogenic product
BR9907883A (en) Vaccine composition, process to elicit an immune response to a herpes simplex virus antigen, and immunogenic composition
BR0212556A (en) interleukin-12 as a veterinary vaccine adjuvant
EP1017283A4 (en) Polynucleotide vaccine formulations
TW221676B (en)
SE9604322D0 (en) Bacterial antigens and vaccine compositions II
DE60036705D1 (en) ADJUVANSKOMBINATIONS FOR IMMUNIZATION AND VACCINE
BR9905780A (en) Vaccine leptospira antigens for the prevention of laptospirosis
DK1204420T3 (en) Trehalose-producing prokaryotic cells as vaccines
DK0563288T3 (en) Immunopotentiation of vaccines, in particular pig pleuropneumonia vaccines

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 13 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 14A E 15A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2255 DE 25/03/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 14A ATE A 21A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.